News
Public · Published
Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven
Carlyle and PAI Partners agreed to sell Theramex, a London-based specialty pharmaceutical company focused on women's health, to rival private equity firm Cinven. The companies did not disclose financial terms, though the Financial Times reported the deal was worth 2.6 billion euros, or $2.9 billion.
Published:
Updated:
What happened
Carlyle and PAI Partners agreed to sell Theramex, a London-based specialty pharmaceutical company focused on women's health, to rival private equity firm Cinven. The companies did not disclose financial terms, though the Financial Times reported the deal was worth 2.6 billion euros, or $2.9 billion.
Confirmed
Global impact / market context
This sale lets Carlyle and PAI exit their investment in Theramex and return cash to their fund investors, which means the money committed to these funds. Cinven gains a women's health business with treatments across menopause, osteoporosis and fertility, expanding its healthcare holdings.
Analyst inference
Private equity firms buy companies using pooled investor money, often with borrowed money, aiming to sell later at a profit. A large healthcare sale signals buyers still see value in specialty pharma, even as the reported 2.6 billion euro price shows such deals remain sizable.
Analyst inference
What to watch
- The companies did not disclose financial terms, so the reported 2.6 billion euro value comes from the Financial Times and is not confirmed by the parties involved in the sale. Confirmed
- Watch whether Cinven outlines plans to expand Theramex's women's health portfolio, since chief executive Robert Stewart said the partners share an ambition to become the global leader in women's health. Proposed
- A completed sale would return capital to Carlyle and PAI investors, which means cash available for new investments, potentially funding future deals and affecting how the firms position themselves. Analyst inference
Evidence
- Original source link unavailable